Beijing Sun-Novo Pharmaceutical Research Past Earnings Performance
Past criteria checks 3/6
Beijing Sun-Novo Pharmaceutical Research has been growing earnings at an average annual rate of 28.1%, while the Life Sciences industry saw earnings growing at 17.2% annually. Revenues have been growing at an average rate of 29.4% per year. Beijing Sun-Novo Pharmaceutical Research's return on equity is 19%, and it has net margins of 19.1%.
Key information
28.1%
Earnings growth rate
21.9%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 29.4% |
| Return on equity | 19.0% |
| Net Margin | 19.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Beijing Sun-Novo Pharmaceutical Research makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,157 | 221 | 225 | 160 |
| 30 Jun 24 | 1,034 | 215 | 222 | 139 |
| 31 Mar 24 | 952 | 210 | 214 | 139 |
| 31 Dec 23 | 932 | 185 | 211 | 124 |
| 30 Sep 23 | 873 | 199 | 159 | 116 |
| 30 Jun 23 | 813 | 187 | 152 | 107 |
| 31 Mar 23 | 761 | 171 | 143 | 92 |
| 31 Dec 22 | 677 | 156 | 129 | 90 |
| 30 Sep 22 | 648 | 149 | 131 | 69 |
| 30 Jun 22 | 594 | 134 | 119 | 64 |
| 31 Mar 22 | 546 | 119 | 107 | 55 |
| 31 Dec 21 | 494 | 106 | 96 | 48 |
| 30 Sep 21 | 454 | 107 | 77 | 50 |
| 30 Jun 21 | 416 | 91 | 71 | 41 |
| 31 Mar 21 | 369 | 76 | 64 | 40 |
| 31 Dec 20 | 347 | 72 | 56 | 34 |
| 31 Dec 19 | 234 | 47 | 34 | 19 |
| 31 Dec 18 | 135 | 21 | 24 | 8 |
Quality Earnings: 688621 has high quality earnings.
Growing Profit Margin: 688621's current net profit margins (19.1%) are lower than last year (22.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688621's earnings have grown significantly by 28.1% per year over the past 5 years.
Accelerating Growth: 688621's earnings growth over the past year (11.4%) is below its 5-year average (28.1% per year).
Earnings vs Industry: 688621 earnings growth over the past year (11.4%) exceeded the Life Sciences industry -14.4%.
Return on Equity
High ROE: 688621's Return on Equity (19%) is considered low.